

12-26-00 03CO Box #3
Seq.
Express Mail No.: EL 501 636 313 US


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bermudes, *et al.*

Application No.: 09/645,415

Filed: August 24, 2000

For: COMPOSITIONS AND METHODS FOR
TUMOR-TARGETED DELIVERY OF
EFFECTOR MOLECULES



Group Art Unit: 1614

Examiner: To be assigned

Attorney Docket No.: 8002-059

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed November 2, 2000, a copy of which is submitted herewith, and in accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

Please replace the paper and computer readable copies of the Sequence Listing filed August 24, 2000 with the paper and computer readable copies of the Substitute Sequence Listing submitted herewith. I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e),

respectively, are the same. I hereby state that the submission herein under 37 C.F. R. § 1.821(g) does not include new matter.

By: *Jennifer Cheda*
Reg No. 46,617



Respectfully submitted,

Date: December 21, 2000

Geraldine F. Baldwin 31,232

Geraldine F. Baldwin

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/645,415	08/24/2000	David G. Bermudes	8002-059-999

20583
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711



FORMALITIES LETTER



OC000000005525376

Date Mailed: 11/02/2000

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37-CFR 1.136(a).

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase PatentIn Software, call (703) 306-2600

*A copy of this notice **MUST** be returned with the reply.*

D. King

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE